MAGraine: Magnesium compared to conventional therapy for treatment of migraines.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc in the context of migraine, published as a randomized controlled trial.

This was a prospective, randomized, double-blind trial.

Pregnant patients, or with renal impairment were excluded.

Who Took Part

The abstract describes 157 patients taking part.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

Adults who presented to the ED with a diagnosis of migraine from August of 2019 to March of 2020 were included.

Patients were randomized to receive intravenous magnesium, prochlorperazine, or metoclopramide.

How the Study Was Run

The design is described as randomized and double-blind.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Vitamin D, K2, Magnesium and Zinc.

What Was Measured

The primary outcome was change in pain from baseline on a numeric rating scale (NRS) evaluated at 30 min after initiation of infusion of study drug.

Secondary outcomes included NRS at 60 and 120 min, ED length of stay, necessity for rescue analgesia, and adverse effects.

Topics PubMed links to this paper include Administration, Intravenous, Magnesium, Metoclopramide, Migraine Disorders, Patient Satisfaction and Prochlorperazine.

Author keywords: Emergency department.

What This Means in Plain Language

The paper is a randomized and double-blind study of Vitamin D, K2, Magnesium and Zinc in 157 patients in people with migraine.

The publication is from 2021 (The American journal of emergency medicine), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, Migraine research.